Humacyte Inc. Common Stock (HUMA)
Stock · NASDAQ · Health Care
$0.4238as of 10/16/2026
Price chart
Active signals
HUMA Signal Track Record
How signals performed across all stocks →What HUMA's price did in the 20 trading sessions after each past signal, compared with any 20-session window over the same period.
| Signal | Times | Median 20-session return | Higher after 20 sessions | Last signal |
|---|---|---|---|---|
| Volume Spike | 44 | -6.2% | 36% | September 16, 2026 |
| Bollinger Band Breakdown | 22 | -7.5% | 36% | September 29, 2026 |
| Bollinger Band Breakout | 23 | -4.0% | 48% | May 28, 2026 |
| 200-Day Moving Average TouchActive now | 12 | +9.6% | 58% | December 27, 2024 |
| Any 20-session window (baseline) | -4.6% | 41% |
Computed by MarketWall from daily closing prices since May 18, 2022. Returns are close-to-close and don't include dividends. Past results describe what happened before; they are not a forecast and not investment advice.
About HUMA
Humacyte, Inc., together with its subsidiaries, engages in the development and manufacture of off-the-shelf, implantable, and bioengineered human tissues for the treatment of diseases and conditions across a range of anatomic locations in multiple therapeutic areas. The company using its proprietary and scientific technology platform to engineer and manufacture human acellular vessels (HAVs) to be implanted into pati…
- Sector
- Health Care
- Industry
- Biotechnology: Biological Products (No Diagnostic Substances)
- Employees
- 184
- Website
- humacyte.com/
Fundamentals
- 1-day range
- $0.3513$0.4456
- Market cap
- $157.54M
- P/E (trailing)
- —
- P/E (forward)
- -1.78
- EPS (trailing)
- $-0.49
- Dividend yield
- —
- Beta
- 2.76
- Avg. volume
- 6.36M
How Humacyte Inc. Common Stock Makes Money
Where the revenue actually goes — FY2025 annual results
Source: 10-K filed Mar 27, 2026 · via SEC EDGAR / Finnhub
Forecasts
6 analyst ratings
Humacyte Inc. Common Stock Competitors
Chosen by industry and closest market cap.
- HUMAHumacyte Inc. Common Stock$0.429▼ 2.50%Market cap $157.54MP/E —$0.337$1.9
- TNYATenaya Therapeutics Inc. Common Stock$0.381▼ 6.62%Market cap $157.50MP/E —$0.3601$2.04
- CRDLCardiol Therapeutics Inc. Class A Common Shares$1.1▼ 4.35%Market cap $156.77MP/E —$1.23$3.23
- CRBUCaribou Biosciences Inc. Common Stock$0.47▲ 1.08%Market cap $162.66MP/E —$0.4425$3.54
- MOLNMolecular Partners AG American Depositary Shares$3.56▼ 2.47%Market cap $163.47MP/E —$2.66$3.96
- LENZLENZ Therapeutics Inc. Common Stock$3.27▼ 8.40%Market cap $163.67MP/E —$3.35$42.98
- ABOSAcumen Pharmaceuticals Inc. Common Stock$1.69▲ 1.20%Market cap $164.68MP/E —$1.5$3.6
| Symbol | Market cap | P/E ratio | Price | 1D | 52-week range |
|---|---|---|---|---|---|
| HUMA Humacyte Inc. Common Stock | $157.54M | — | $0.429 | ▼ 2.50% | $0.337$1.9 |
| TNYA Tenaya Therapeutics Inc. Common Stock | $157.50M | — | $0.381 | ▼ 6.62% | $0.3601$2.04 |
| CRDL Cardiol Therapeutics Inc. Class A Common Shares | $156.77M | — | $1.1 | ▼ 4.35% | $1.23$3.23 |
| CRBU Caribou Biosciences Inc. Common Stock | $162.66M | — | $0.47 | ▲ 1.08% | $0.4425$3.54 |
| MOLN Molecular Partners AG American Depositary Shares | $163.47M | — | $3.56 | ▼ 2.47% | $2.66$3.96 |
| LENZ LENZ Therapeutics Inc. Common Stock | $163.67M | — | $3.27 | ▼ 8.40% | $3.35$42.98 |
| ABOS Acumen Pharmaceuticals Inc. Common Stock | $164.68M | — | $1.69 | ▲ 1.20% | $1.5$3.6 |
P/E shows — for peers not currently carrying a live signal of their own.
Latest news
- Humacyte Reports Accelerating Commercial Adoption, Reports 44% Increase In Hospitals Ordering Symvess To 49 In Q3 2026benzinga · 10/15/2026
- Humacyte (HUMA) Stock Fair Value Moves Lower After Analyst Target CutsYahoo · 10/9/2026
- Intel downgraded, Marvell upgraded: Wall Street's top analyst callsYahoo · 10/7/2026
- Barclays Initiates Coverage On Humacyte with Equal-Weight Rating, Announces Price Target of $0.5Benzinga · 10/7/2026
- Humacyte, Inc. (HUMA) Stock Slides as Market Rises: Facts to Know Before You TradeYahoo · 10/6/2026
- Humacyte, Inc. (HUMA) Stock Drops Despite Market Gains: Important Facts to NoteYahoo · 10/1/2026
- Humacyte Expands Board Expertise with Appointment of Scott Coward and Paul KuznikYahoo · 9/28/2026
- Humacyte, Inc. (HUMA) Stock Sinks As Market Gains: Here's WhyYahoo · 9/25/2026
- Humacyte, Inc. (HUMA) Beats Stock Market Upswing: What Investors Need to KnowYahoo · 9/18/2026
Insider Activity
Insider Actions →- Kuznik Paul Brian · October 6, 2026 · Grant125.0K
- COWARD D SCOTT · October 6, 2026 · Grant125.0K
- Jones Keith Anthony · September 14, 2026 · Buy10.0K @ $0.562
- Jones Keith Anthony · August 20, 2026 · Buy10.0K @ $0.693
- Jones Keith Anthony · August 17, 2026 · Buy30.0K @ $0.594
- Wallace Max N. · June 11, 2026 · Grant80.0K
- Charles Bruce Green · June 11, 2026 · Grant80.0K
- Seimetz Diane · June 11, 2026 · Grant80.0K
- Bamforth John Philip · June 11, 2026 · Grant80.0K
- Brown Emery N. · June 11, 2026 · Grant80.0K
- Brady W. Dougan · June 11, 2026 · Grant0
- Windham-Bannister Susan Richards · June 11, 2026 · Grant80.0K
- Laura E. Niklason · June 11, 2026 · Grant80.0K
- Jones Keith Anthony · June 11, 2026 · Grant80.0K
- Michael T. Constantino · June 11, 2026 · Grant80.0K
Institutional Ownership
March 31, 2026
- Total shares held
- 58.25M
- Total value held
- $35.13M
- Institutional holders
- 156
- Unknown12.32M
- Unknown7.16M
- Unknown5.72M
- Unknown3.75M
- Unknown3.66M
- Unknown3.04M
- Unknown2.78M
- Unknown2.00M
- Unknown1.92M
- Unknown1.76M
See the full, filterable feed with live charts on the MarketWall dashboard.
AI Market Commentary
AI-generatedAll commentary →Synthesized from recent news and fundamentals/technical data -- not human analyst commentary or trader sentiment.
September 28, 2026
Humacyte Adds Scott Coward and Paul Kuznik to Board
Humacyte added Scott Coward and Paul Kuznik to its board, expanding expertise in regulatory and clinical areas. The move comes as the stock fell 4% in a broader market rally, reflecting short‑term price pressure rather than a change in fundamentals. The new directors bring experience that could support the company’s tissue engineering pipeline, but the current price remains below the 52‑week low.
Humacyte Adds Scott Coward and Paul Kuznik to Board. Humacyte added Scott Coward and Paul Kuznik to its board, expanding expertise in regulatory and clinical areas. The move comes as the stock fell 4% in a broader market rally, reflecting short‑term price pressure rather than a change in fundamentals. The new directors bring experience that could support the company’s tissue engineering pipeline, but the current price remains below the 52‑week low.